Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Smoking Cessation | 53 | 2024 | 2056 | 7.240 |
Why?
|
Tobacco Use Disorder | 30 | 2024 | 703 | 6.180 |
Why?
|
Cannabis | 17 | 2024 | 441 | 4.580 |
Why?
|
Nicotinic Agonists | 19 | 2021 | 265 | 4.210 |
Why?
|
Marijuana Abuse | 12 | 2024 | 410 | 4.070 |
Why?
|
Bupropion | 20 | 2022 | 304 | 3.680 |
Why?
|
Nicotine | 18 | 2024 | 678 | 3.180 |
Why?
|
Schizophrenia | 54 | 2024 | 6930 | 3.120 |
Why?
|
Marijuana Smoking | 8 | 2019 | 258 | 3.070 |
Why?
|
Smoking | 39 | 2024 | 9055 | 2.430 |
Why?
|
Tobacco Use Cessation | 5 | 2023 | 94 | 2.370 |
Why?
|
Reward | 10 | 2024 | 968 | 1.830 |
Why?
|
Schizophrenic Psychology | 21 | 2017 | 1645 | 1.630 |
Why?
|
Quinoxalines | 6 | 2021 | 296 | 1.490 |
Why?
|
Benzazepines | 6 | 2021 | 310 | 1.480 |
Why?
|
Antipsychotic Agents | 29 | 2020 | 3064 | 1.410 |
Why?
|
Substance Withdrawal Syndrome | 6 | 2023 | 624 | 1.180 |
Why?
|
Double-Blind Method | 45 | 2024 | 12341 | 1.170 |
Why?
|
Cues | 7 | 2018 | 875 | 1.150 |
Why?
|
Dopamine Uptake Inhibitors | 5 | 2016 | 297 | 1.120 |
Why?
|
Mental Disorders | 12 | 2024 | 6823 | 1.090 |
Why?
|
Cycloserine | 6 | 2018 | 118 | 1.070 |
Why?
|
Psychotic Disorders | 16 | 2022 | 3220 | 0.980 |
Why?
|
Substance-Related Disorders | 9 | 2024 | 4413 | 0.950 |
Why?
|
Behavior, Addictive | 5 | 2024 | 462 | 0.880 |
Why?
|
Bipolar Disorder | 8 | 2019 | 5092 | 0.880 |
Why?
|
Attention | 12 | 2019 | 2394 | 0.850 |
Why?
|
Cannabidiol | 2 | 2022 | 118 | 0.820 |
Why?
|
Adult | 116 | 2024 | 221120 | 0.790 |
Why?
|
Peer Group | 3 | 2019 | 691 | 0.780 |
Why?
|
Clozapine | 14 | 2010 | 504 | 0.770 |
Why?
|
Motivation | 5 | 2024 | 2002 | 0.750 |
Why?
|
Cross-Over Studies | 10 | 2024 | 2082 | 0.690 |
Why?
|
Depressive Disorder, Major | 8 | 2023 | 4767 | 0.680 |
Why?
|
Implosive Therapy | 2 | 2018 | 125 | 0.670 |
Why?
|
Impulsive Behavior | 3 | 2024 | 346 | 0.670 |
Why?
|
Cerebral Cortex | 8 | 2024 | 5775 | 0.650 |
Why?
|
Adolescent Behavior | 3 | 2024 | 1188 | 0.640 |
Why?
|
Anxiety Disorders | 8 | 2023 | 2723 | 0.630 |
Why?
|
Young Adult | 37 | 2024 | 59222 | 0.620 |
Why?
|
Adolescent | 41 | 2024 | 88300 | 0.600 |
Why?
|
Spectroscopy, Near-Infrared | 2 | 2024 | 740 | 0.600 |
Why?
|
Behavior Therapy | 6 | 2024 | 875 | 0.600 |
Why?
|
Mood Disorders | 4 | 2022 | 1124 | 0.590 |
Why?
|
Humans | 168 | 2024 | 761222 | 0.580 |
Why?
|
Anticipation, Psychological | 1 | 2018 | 84 | 0.580 |
Why?
|
Brain | 17 | 2024 | 27094 | 0.570 |
Why?
|
Sleep Initiation and Maintenance Disorders | 3 | 2024 | 1081 | 0.550 |
Why?
|
Female | 111 | 2024 | 392552 | 0.520 |
Why?
|
Risperidone | 5 | 2010 | 381 | 0.520 |
Why?
|
Verbal Learning | 3 | 2019 | 463 | 0.510 |
Why?
|
Prefrontal Cortex | 4 | 2024 | 2219 | 0.510 |
Why?
|
Male | 102 | 2024 | 360703 | 0.500 |
Why?
|
Cholinesterase Inhibitors | 3 | 2008 | 241 | 0.500 |
Why?
|
Glycine | 3 | 2011 | 659 | 0.500 |
Why?
|
Middle Aged | 75 | 2024 | 220858 | 0.480 |
Why?
|
Cotinine | 3 | 2022 | 206 | 0.480 |
Why?
|
Antidepressive Agents, Second-Generation | 4 | 2015 | 489 | 0.470 |
Why?
|
Self Care | 1 | 2020 | 795 | 0.470 |
Why?
|
Risk-Taking | 2 | 2023 | 1038 | 0.470 |
Why?
|
Self Report | 5 | 2024 | 3727 | 0.460 |
Why?
|
Reaction Time | 8 | 2019 | 2087 | 0.460 |
Why?
|
Mecamylamine | 1 | 2013 | 27 | 0.450 |
Why?
|
Neurofeedback | 1 | 2014 | 44 | 0.450 |
Why?
|
Brain Mapping | 5 | 2019 | 6635 | 0.440 |
Why?
|
Memory | 5 | 2018 | 2190 | 0.430 |
Why?
|
Nicotinic Antagonists | 1 | 2013 | 94 | 0.430 |
Why?
|
Cognition | 8 | 2024 | 6988 | 0.430 |
Why?
|
Propranolol | 1 | 2014 | 490 | 0.420 |
Why?
|
Magnetic Resonance Imaging | 16 | 2024 | 36415 | 0.410 |
Why?
|
Corpus Striatum | 2 | 2018 | 1234 | 0.400 |
Why?
|
Choice Behavior | 2 | 2015 | 825 | 0.400 |
Why?
|
Maternal Behavior | 1 | 2014 | 307 | 0.400 |
Why?
|
Psychiatric Status Rating Scales | 17 | 2017 | 6011 | 0.380 |
Why?
|
Alcoholism | 3 | 2018 | 1973 | 0.370 |
Why?
|
Fluoxetine | 1 | 2015 | 728 | 0.370 |
Why?
|
Neuropsychological Tests | 12 | 2021 | 7046 | 0.360 |
Why?
|
Mother-Child Relations | 1 | 2014 | 495 | 0.360 |
Why?
|
Antimanic Agents | 2 | 2006 | 520 | 0.360 |
Why?
|
Narcotic Antagonists | 3 | 2014 | 585 | 0.350 |
Why?
|
Drug Therapy, Combination | 16 | 2018 | 6304 | 0.340 |
Why?
|
Weight Gain | 4 | 2023 | 2349 | 0.340 |
Why?
|
Social Environment | 1 | 2015 | 1022 | 0.340 |
Why?
|
Patient Education as Topic | 1 | 2020 | 2317 | 0.340 |
Why?
|
Administration, Cutaneous | 6 | 2011 | 713 | 0.340 |
Why?
|
Delayed-Action Preparations | 8 | 2011 | 961 | 0.340 |
Why?
|
Alcohol Drinking | 2 | 2020 | 4027 | 0.340 |
Why?
|
Pyrrolidines | 1 | 2011 | 339 | 0.330 |
Why?
|
Treatment Outcome | 35 | 2024 | 64681 | 0.330 |
Why?
|
Analysis of Variance | 7 | 2016 | 6223 | 0.330 |
Why?
|
Combined Modality Therapy | 10 | 2018 | 8519 | 0.320 |
Why?
|
Cognition Disorders | 8 | 2009 | 3976 | 0.320 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2014 | 1241 | 0.320 |
Why?
|
Indans | 2 | 2006 | 92 | 0.310 |
Why?
|
Cholinergic Agonists | 1 | 2008 | 75 | 0.300 |
Why?
|
Galantamine | 1 | 2008 | 33 | 0.300 |
Why?
|
Cocaine-Related Disorders | 2 | 2008 | 460 | 0.300 |
Why?
|
Psychomotor Performance | 4 | 2011 | 1880 | 0.290 |
Why?
|
Mental Recall | 2 | 2016 | 1221 | 0.280 |
Why?
|
Randomized Controlled Trials as Topic | 9 | 2022 | 10218 | 0.270 |
Why?
|
Nerve Net | 2 | 2019 | 2288 | 0.270 |
Why?
|
Valproic Acid | 2 | 2006 | 443 | 0.270 |
Why?
|
Receptors, N-Methyl-D-Aspartate | 1 | 2011 | 894 | 0.260 |
Why?
|
Anxiety | 3 | 2024 | 4569 | 0.260 |
Why?
|
Quinolines | 1 | 2011 | 764 | 0.260 |
Why?
|
Memory, Short-Term | 3 | 2024 | 982 | 0.260 |
Why?
|
Suicide | 1 | 2017 | 1602 | 0.260 |
Why?
|
Benzodiazepines | 8 | 2020 | 1134 | 0.250 |
Why?
|
Depression | 4 | 2024 | 8132 | 0.250 |
Why?
|
Lithium Carbonate | 1 | 2006 | 179 | 0.250 |
Why?
|
Decision Making | 2 | 2016 | 3931 | 0.250 |
Why?
|
Suicidal Ideation | 2 | 2024 | 1447 | 0.250 |
Why?
|
Inositol | 1 | 2006 | 215 | 0.250 |
Why?
|
Image Processing, Computer-Assisted | 6 | 2016 | 8998 | 0.240 |
Why?
|
Time Factors | 11 | 2020 | 39957 | 0.230 |
Why?
|
Emotions | 3 | 2014 | 2742 | 0.220 |
Why?
|
Psychoses, Substance-Induced | 2 | 2016 | 99 | 0.220 |
Why?
|
Comorbidity | 10 | 2019 | 10516 | 0.210 |
Why?
|
Tandem Mass Spectrometry | 2 | 2019 | 1186 | 0.210 |
Why?
|
Massachusetts | 3 | 2021 | 8837 | 0.210 |
Why?
|
Cannabinoids | 2 | 2024 | 172 | 0.200 |
Why?
|
Legislation, Drug | 2 | 2022 | 214 | 0.200 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 1 | 2017 | 3707 | 0.200 |
Why?
|
Hazardous Substances | 1 | 2022 | 153 | 0.190 |
Why?
|
Television | 1 | 2024 | 407 | 0.190 |
Why?
|
Excitatory Amino Acid Agonists | 2 | 1999 | 142 | 0.190 |
Why?
|
Single-Blind Method | 2 | 2022 | 1577 | 0.190 |
Why?
|
Glutamic Acid | 3 | 2011 | 1173 | 0.190 |
Why?
|
Patient Dropouts | 2 | 2017 | 411 | 0.190 |
Why?
|
Gyrus Cinguli | 3 | 2017 | 1114 | 0.190 |
Why?
|
Placebos | 7 | 2009 | 1666 | 0.180 |
Why?
|
Registries | 1 | 2017 | 8246 | 0.180 |
Why?
|
Piperidines | 2 | 2006 | 1656 | 0.180 |
Why?
|
Hallucinogens | 1 | 2024 | 197 | 0.170 |
Why?
|
Naltrexone | 3 | 2014 | 317 | 0.170 |
Why?
|
Follow-Up Studies | 11 | 2020 | 39127 | 0.170 |
Why?
|
Carbon Monoxide | 2 | 2017 | 547 | 0.160 |
Why?
|
Dopamine Agonists | 2 | 2014 | 352 | 0.160 |
Why?
|
Ownership | 1 | 2022 | 340 | 0.160 |
Why?
|
Intention to Treat Analysis | 1 | 2020 | 413 | 0.160 |
Why?
|
Limit of Detection | 1 | 2019 | 273 | 0.160 |
Why?
|
Diagnostic and Statistical Manual of Mental Disorders | 6 | 2008 | 1990 | 0.150 |
Why?
|
Recurrence | 5 | 2017 | 8457 | 0.150 |
Why?
|
Cardiovascular Diseases | 5 | 2020 | 15521 | 0.150 |
Why?
|
Antidepressive Agents | 2 | 2011 | 2893 | 0.150 |
Why?
|
Psychological Tests | 2 | 2018 | 639 | 0.150 |
Why?
|
Heart Rate | 3 | 2024 | 4197 | 0.150 |
Why?
|
Regression Analysis | 3 | 2022 | 6345 | 0.150 |
Why?
|
Psychotherapy, Group | 1 | 2021 | 413 | 0.150 |
Why?
|
Glycemic Index | 1 | 2020 | 396 | 0.150 |
Why?
|
Piperazines | 4 | 2009 | 2522 | 0.140 |
Why?
|
Benzothiazoles | 2 | 2009 | 248 | 0.140 |
Why?
|
Linear Models | 3 | 2016 | 5869 | 0.140 |
Why?
|
Antiparkinson Agents | 1 | 1998 | 184 | 0.140 |
Why?
|
Pyrenes | 1 | 2017 | 49 | 0.140 |
Why?
|
Cross-Sectional Studies | 15 | 2024 | 26072 | 0.140 |
Why?
|
Weight Loss | 2 | 2019 | 2680 | 0.140 |
Why?
|
Receptors, Dopamine D2 | 3 | 2009 | 485 | 0.140 |
Why?
|
Nitrosamines | 1 | 2017 | 87 | 0.140 |
Why?
|
Substance Abuse Detection | 1 | 2019 | 301 | 0.140 |
Why?
|
Aged | 16 | 2024 | 169292 | 0.130 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2020 | 12159 | 0.130 |
Why?
|
Caudate Nucleus | 1 | 2017 | 390 | 0.130 |
Why?
|
Brief Psychiatric Rating Scale | 2 | 2006 | 108 | 0.130 |
Why?
|
Perception | 1 | 2022 | 1198 | 0.130 |
Why?
|
Cyclobutanes | 2 | 2007 | 57 | 0.130 |
Why?
|
Dose-Response Relationship, Drug | 6 | 2012 | 10756 | 0.130 |
Why?
|
Immunoassay | 1 | 2019 | 743 | 0.130 |
Why?
|
Depressive Disorder | 1 | 2008 | 3727 | 0.130 |
Why?
|
Limbic System | 1 | 1998 | 419 | 0.130 |
Why?
|
Finland | 1 | 2017 | 607 | 0.130 |
Why?
|
Chromatography, Liquid | 1 | 2019 | 982 | 0.130 |
Why?
|
Appetite Depressants | 2 | 2007 | 108 | 0.130 |
Why?
|
Pennsylvania | 1 | 2017 | 612 | 0.130 |
Why?
|
Basal Ganglia | 1 | 1998 | 554 | 0.120 |
Why?
|
Personality | 1 | 2019 | 553 | 0.120 |
Why?
|
Antimetabolites | 1 | 2015 | 129 | 0.120 |
Why?
|
United States | 11 | 2024 | 72341 | 0.120 |
Why?
|
Smoke | 1 | 2017 | 236 | 0.120 |
Why?
|
Drug Administration Schedule | 4 | 2008 | 4851 | 0.120 |
Why?
|
Behavior | 2 | 2016 | 540 | 0.120 |
Why?
|
Discriminant Analysis | 1 | 2015 | 224 | 0.120 |
Why?
|
Gastrectomy | 1 | 2019 | 672 | 0.120 |
Why?
|
Rest | 1 | 2019 | 920 | 0.120 |
Why?
|
Aspartic Acid | 1 | 1997 | 574 | 0.120 |
Why?
|
Neurotransmitter Agents | 1 | 1998 | 664 | 0.110 |
Why?
|
Quinolones | 2 | 2009 | 378 | 0.110 |
Why?
|
Longitudinal Studies | 5 | 2023 | 14610 | 0.110 |
Why?
|
Low Back Pain | 1 | 2022 | 983 | 0.110 |
Why?
|
Risk Reduction Behavior | 1 | 2020 | 1111 | 0.110 |
Why?
|
Magnetic Resonance Spectroscopy | 3 | 2011 | 3770 | 0.110 |
Why?
|
Tobacco Smoke Pollution | 1 | 2019 | 821 | 0.110 |
Why?
|
Internationality | 1 | 2019 | 999 | 0.110 |
Why?
|
Probability | 2 | 2016 | 2478 | 0.110 |
Why?
|
Friends | 1 | 2014 | 148 | 0.110 |
Why?
|
Hyperprolactinemia | 1 | 2014 | 124 | 0.110 |
Why?
|
Social Facilitation | 1 | 2012 | 31 | 0.110 |
Why?
|
Ambulatory Care | 6 | 2008 | 2770 | 0.100 |
Why?
|
Risk | 2 | 2017 | 9616 | 0.100 |
Why?
|
Anticonvulsants | 1 | 2003 | 1910 | 0.100 |
Why?
|
Galvanic Skin Response | 1 | 2014 | 358 | 0.100 |
Why?
|
Taurine | 1 | 2012 | 92 | 0.100 |
Why?
|
Telecommunications | 1 | 2012 | 79 | 0.100 |
Why?
|
Creatine | 3 | 2011 | 427 | 0.100 |
Why?
|
Extinction, Psychological | 1 | 2015 | 371 | 0.100 |
Why?
|
Dysthymic Disorder | 1 | 2011 | 75 | 0.090 |
Why?
|
Multivariate Analysis | 2 | 2019 | 12052 | 0.090 |
Why?
|
Bariatric Surgery | 2 | 2019 | 991 | 0.090 |
Why?
|
Clinical Protocols | 1 | 2017 | 1436 | 0.090 |
Why?
|
Receptors, Dopamine D3 | 2 | 2009 | 108 | 0.090 |
Why?
|
Pain | 2 | 2024 | 5072 | 0.090 |
Why?
|
Neural Pathways | 2 | 2019 | 3056 | 0.090 |
Why?
|
Feasibility Studies | 2 | 2023 | 5250 | 0.090 |
Why?
|
Cohort Studies | 4 | 2024 | 41496 | 0.090 |
Why?
|
Remission Induction | 1 | 2016 | 2392 | 0.090 |
Why?
|
Citalopram | 1 | 2012 | 402 | 0.080 |
Why?
|
Social Behavior | 1 | 2016 | 1136 | 0.080 |
Why?
|
Self-Help Groups | 1 | 2011 | 192 | 0.080 |
Why?
|
Dogs | 1 | 2014 | 3832 | 0.080 |
Why?
|
Inpatients | 1 | 2021 | 2545 | 0.080 |
Why?
|
Task Performance and Analysis | 1 | 2013 | 763 | 0.080 |
Why?
|
Diffusion Tensor Imaging | 1 | 2019 | 2401 | 0.080 |
Why?
|
Boston | 2 | 2024 | 9327 | 0.080 |
Why?
|
Polymethacrylic Acids | 1 | 2008 | 32 | 0.080 |
Why?
|
Chewing Gum | 1 | 2008 | 40 | 0.080 |
Why?
|
Feeding Behavior | 2 | 2019 | 3183 | 0.080 |
Why?
|
Outpatients | 1 | 2017 | 1598 | 0.080 |
Why?
|
Medicaid | 1 | 2022 | 2813 | 0.080 |
Why?
|
Naloxone | 2 | 2013 | 370 | 0.080 |
Why?
|
Memory Disorders | 1 | 2016 | 1198 | 0.080 |
Why?
|
Obesity, Morbid | 1 | 2019 | 1278 | 0.080 |
Why?
|
United States Food and Drug Administration | 1 | 2017 | 1662 | 0.080 |
Why?
|
Receptors, Nicotinic | 1 | 2011 | 494 | 0.070 |
Why?
|
Obesity | 7 | 2020 | 12940 | 0.070 |
Why?
|
Pilot Projects | 6 | 2017 | 8642 | 0.070 |
Why?
|
Polyvinyls | 1 | 2008 | 154 | 0.070 |
Why?
|
Severity of Illness Index | 4 | 2019 | 15841 | 0.070 |
Why?
|
Blood Glucose | 6 | 2010 | 6392 | 0.070 |
Why?
|
Phosphodiesterase Inhibitors | 1 | 2008 | 213 | 0.070 |
Why?
|
Anthropometry | 2 | 2009 | 1338 | 0.070 |
Why?
|
Health Behavior | 1 | 2019 | 2641 | 0.070 |
Why?
|
Opioid-Related Disorders | 1 | 2022 | 2164 | 0.070 |
Why?
|
Practice Guidelines as Topic | 2 | 2020 | 7400 | 0.070 |
Why?
|
Stress Disorders, Post-Traumatic | 2 | 2019 | 4575 | 0.070 |
Why?
|
Diabetes Mellitus | 4 | 2020 | 5842 | 0.070 |
Why?
|
Oxygen | 2 | 2016 | 4228 | 0.070 |
Why?
|
Injections, Intramuscular | 1 | 2008 | 555 | 0.070 |
Why?
|
Causality | 1 | 2012 | 1244 | 0.070 |
Why?
|
Psychometrics | 3 | 2023 | 3061 | 0.060 |
Why?
|
Dibenzothiazepines | 1 | 2006 | 102 | 0.060 |
Why?
|
Association Learning | 1 | 2007 | 221 | 0.060 |
Why?
|
Sensitivity and Specificity | 2 | 2015 | 14675 | 0.060 |
Why?
|
Sulfones | 1 | 2008 | 448 | 0.060 |
Why?
|
Oxidative Stress | 1 | 2017 | 3114 | 0.060 |
Why?
|
Genetic Predisposition to Disease | 3 | 2013 | 17897 | 0.060 |
Why?
|
Age of Onset | 1 | 2012 | 3307 | 0.060 |
Why?
|
Waist Circumference | 1 | 2009 | 933 | 0.060 |
Why?
|
Child | 4 | 2024 | 80154 | 0.060 |
Why?
|
Glucose | 4 | 2010 | 4342 | 0.060 |
Why?
|
Prospective Studies | 2 | 2020 | 54437 | 0.060 |
Why?
|
Reproducibility of Results | 3 | 2021 | 20118 | 0.060 |
Why?
|
Secondary Prevention | 1 | 2011 | 1472 | 0.060 |
Why?
|
Data Interpretation, Statistical | 1 | 2015 | 2691 | 0.060 |
Why?
|
Pyridines | 1 | 2017 | 2872 | 0.060 |
Why?
|
Risk Factors | 7 | 2020 | 74241 | 0.060 |
Why?
|
Insulin Resistance | 5 | 2010 | 3952 | 0.060 |
Why?
|
Glucose Tolerance Test | 4 | 2010 | 1178 | 0.060 |
Why?
|
Gross Domestic Product | 1 | 2024 | 77 | 0.060 |
Why?
|
Predictive Value of Tests | 2 | 2019 | 15308 | 0.060 |
Why?
|
Lithium Compounds | 1 | 2006 | 223 | 0.060 |
Why?
|
Case-Control Studies | 3 | 2017 | 22174 | 0.060 |
Why?
|
Sample Size | 1 | 2007 | 843 | 0.060 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2007 | 360 | 0.060 |
Why?
|
Models, Biological | 2 | 2019 | 9458 | 0.050 |
Why?
|
Morbidity | 2 | 2009 | 1751 | 0.050 |
Why?
|
Quality of Life | 4 | 2022 | 13367 | 0.050 |
Why?
|
Hyperlipidemias | 2 | 2005 | 771 | 0.050 |
Why?
|
Incidence | 2 | 2017 | 21366 | 0.050 |
Why?
|
Buprenorphine | 2 | 2013 | 656 | 0.050 |
Why?
|
Long QT Syndrome | 1 | 2008 | 466 | 0.050 |
Why?
|
Tobacco Industry | 1 | 2024 | 136 | 0.050 |
Why?
|
Counseling | 2 | 2022 | 1536 | 0.050 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 4567 | 0.050 |
Why?
|
Benzhydryl Compounds | 1 | 2009 | 917 | 0.050 |
Why?
|
Arousal | 1 | 2008 | 1171 | 0.050 |
Why?
|
Marketing | 1 | 2024 | 220 | 0.050 |
Why?
|
Dietary Fats | 1 | 2010 | 1994 | 0.050 |
Why?
|
Pirenzepine | 1 | 2002 | 116 | 0.050 |
Why?
|
Thiazoles | 1 | 2009 | 1517 | 0.050 |
Why?
|
Diagnosis, Dual (Psychiatry) | 2 | 2012 | 303 | 0.050 |
Why?
|
Computer Simulation | 1 | 2015 | 6224 | 0.050 |
Why?
|
Homocysteine | 1 | 2004 | 637 | 0.050 |
Why?
|
Hospitalization | 1 | 2021 | 10707 | 0.050 |
Why?
|
Hypertension | 3 | 2020 | 8536 | 0.050 |
Why?
|
Internship and Residency | 1 | 2021 | 5885 | 0.050 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2022 | 326 | 0.050 |
Why?
|
Central Nervous System Stimulants | 1 | 2009 | 1176 | 0.040 |
Why?
|
Child, Preschool | 2 | 2014 | 42225 | 0.040 |
Why?
|
Social Control, Formal | 1 | 2001 | 107 | 0.040 |
Why?
|
Receptors, GABA | 1 | 2022 | 312 | 0.040 |
Why?
|
Research Design | 2 | 2015 | 6180 | 0.040 |
Why?
|
Electronics | 1 | 2021 | 317 | 0.040 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2022 | 628 | 0.040 |
Why?
|
Drug Resistance | 1 | 2006 | 1594 | 0.040 |
Why?
|
New York | 1 | 2022 | 875 | 0.040 |
Why?
|
Learning | 1 | 2009 | 1737 | 0.040 |
Why?
|
Prescriptions | 1 | 2022 | 386 | 0.040 |
Why?
|
Body Weight | 5 | 2009 | 4618 | 0.040 |
Why?
|
Placebo Effect | 1 | 2003 | 518 | 0.040 |
Why?
|
Evidence-Based Medicine | 1 | 2011 | 3691 | 0.040 |
Why?
|
Mental Health | 2 | 2024 | 3251 | 0.040 |
Why?
|
Haloperidol | 1 | 2020 | 390 | 0.040 |
Why?
|
Reinforcement Schedule | 2 | 2009 | 123 | 0.040 |
Why?
|
Nerve Tissue Proteins | 1 | 2011 | 4404 | 0.040 |
Why?
|
Bronchiolitis | 1 | 2004 | 485 | 0.040 |
Why?
|
Child Behavior | 1 | 2024 | 848 | 0.040 |
Why?
|
Body Mass Index | 7 | 2009 | 12952 | 0.040 |
Why?
|
Folic Acid | 1 | 2004 | 1323 | 0.040 |
Why?
|
Polymorphism, Genetic | 1 | 2007 | 4243 | 0.040 |
Why?
|
Gene Expression | 1 | 2010 | 7571 | 0.030 |
Why?
|
Clinical Trials as Topic | 2 | 2003 | 8002 | 0.030 |
Why?
|
Anisotropy | 1 | 2019 | 1284 | 0.030 |
Why?
|
Lung Diseases, Interstitial | 1 | 2004 | 918 | 0.030 |
Why?
|
Multifactorial Inheritance | 1 | 2024 | 1387 | 0.030 |
Why?
|
Attitude to Health | 1 | 2004 | 2026 | 0.030 |
Why?
|
Suicide, Attempted | 1 | 2024 | 1402 | 0.030 |
Why?
|
Cytokines | 1 | 2010 | 7386 | 0.030 |
Why?
|
Random Allocation | 1 | 2019 | 2393 | 0.030 |
Why?
|
Ergolines | 1 | 2014 | 57 | 0.030 |
Why?
|
Basal Ganglia Diseases | 2 | 2004 | 145 | 0.030 |
Why?
|
Social Support | 1 | 2024 | 2175 | 0.030 |
Why?
|
Cholesterol | 3 | 2009 | 2902 | 0.030 |
Why?
|
Students | 1 | 2024 | 1737 | 0.030 |
Why?
|
Logistic Models | 1 | 2008 | 13249 | 0.030 |
Why?
|
Age Factors | 3 | 2018 | 18384 | 0.030 |
Why?
|
Frontal Lobe | 1 | 2019 | 1416 | 0.030 |
Why?
|
Pneumonia | 1 | 2004 | 2142 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2021 | 2329 | 0.030 |
Why?
|
Animals | 2 | 2015 | 168089 | 0.030 |
Why?
|
Psychiatry | 1 | 2005 | 1699 | 0.030 |
Why?
|
Psychotropic Drugs | 1 | 2018 | 885 | 0.030 |
Why?
|
Infant, Newborn | 1 | 2012 | 26200 | 0.030 |
Why?
|
International Cooperation | 1 | 2018 | 1423 | 0.020 |
Why?
|
Sex Characteristics | 1 | 2021 | 2640 | 0.020 |
Why?
|
Pregnancy | 1 | 2012 | 29893 | 0.020 |
Why?
|
Stroop Test | 1 | 2010 | 71 | 0.020 |
Why?
|
Infant | 1 | 2012 | 36170 | 0.020 |
Why?
|
Administration, Oral | 2 | 2009 | 4015 | 0.020 |
Why?
|
Triglycerides | 2 | 2009 | 2457 | 0.020 |
Why?
|
Blood Pressure | 2 | 2020 | 8479 | 0.020 |
Why?
|
Feedback, Psychological | 1 | 2009 | 96 | 0.020 |
Why?
|
Lipids | 1 | 2020 | 3331 | 0.020 |
Why?
|
Internal-External Control | 1 | 2010 | 358 | 0.020 |
Why?
|
Life Style | 1 | 2020 | 3907 | 0.020 |
Why?
|
Alleles | 2 | 2011 | 6857 | 0.020 |
Why?
|
Diet Records | 1 | 2010 | 427 | 0.020 |
Why?
|
Prognosis | 2 | 2019 | 29688 | 0.020 |
Why?
|
Sleep | 1 | 2023 | 4759 | 0.020 |
Why?
|
Connective Tissue | 1 | 1990 | 419 | 0.020 |
Why?
|
Motor Activity | 1 | 2017 | 2712 | 0.020 |
Why?
|
Occipital Lobe | 1 | 2009 | 374 | 0.020 |
Why?
|
Principal Component Analysis | 1 | 2010 | 942 | 0.020 |
Why?
|
Hippocampus | 1 | 2019 | 3754 | 0.020 |
Why?
|
Food Preferences | 1 | 2010 | 398 | 0.020 |
Why?
|
Lung | 1 | 2004 | 9979 | 0.020 |
Why?
|
Analgesics, Opioid | 1 | 2022 | 3805 | 0.020 |
Why?
|
Sialorrhea | 1 | 2005 | 25 | 0.020 |
Why?
|
Pneumothorax | 1 | 1989 | 386 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2019 | 7804 | 0.020 |
Why?
|
Community Mental Health Centers | 1 | 2006 | 93 | 0.020 |
Why?
|
Discrimination Learning | 1 | 2007 | 278 | 0.020 |
Why?
|
Health Status | 2 | 2009 | 4077 | 0.020 |
Why?
|
Capsules | 1 | 2005 | 191 | 0.020 |
Why?
|
Purines | 1 | 2008 | 609 | 0.020 |
Why?
|
Dyskinesias | 1 | 2005 | 79 | 0.020 |
Why?
|
Mass Screening | 1 | 2021 | 5426 | 0.010 |
Why?
|
Dizziness | 1 | 2007 | 258 | 0.010 |
Why?
|
Health Services Accessibility | 1 | 2022 | 5426 | 0.010 |
Why?
|
Cause of Death | 2 | 2005 | 3688 | 0.010 |
Why?
|
Nausea | 1 | 2007 | 678 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 2010 | 2854 | 0.010 |
Why?
|
Glutamate Carboxypeptidase II | 1 | 2004 | 82 | 0.010 |
Why?
|
Prevalence | 2 | 2014 | 15721 | 0.010 |
Why?
|
Protons | 1 | 2009 | 1111 | 0.010 |
Why?
|
Bronchoscopy | 1 | 1989 | 909 | 0.010 |
Why?
|
Exercise | 1 | 2020 | 5874 | 0.010 |
Why?
|
Evoked Potentials | 1 | 2009 | 1047 | 0.010 |
Why?
|
Eating | 1 | 2010 | 1535 | 0.010 |
Why?
|
Nutrition Assessment | 1 | 2006 | 727 | 0.010 |
Why?
|
Prostheses and Implants | 1 | 1990 | 1273 | 0.010 |
Why?
|
Life Change Events | 1 | 2008 | 952 | 0.010 |
Why?
|
Radiography, Thoracic | 1 | 1989 | 1302 | 0.010 |
Why?
|
Stereotyping | 1 | 2004 | 239 | 0.010 |
Why?
|
Wakefulness | 1 | 2009 | 1264 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2021 | 12676 | 0.010 |
Why?
|
Fatigue | 1 | 2009 | 1550 | 0.010 |
Why?
|
Confidence Intervals | 1 | 2007 | 2928 | 0.010 |
Why?
|
Cardiomegaly | 1 | 2004 | 590 | 0.010 |
Why?
|
Retrospective Studies | 2 | 2007 | 80675 | 0.010 |
Why?
|
Psychotherapy | 1 | 2011 | 1646 | 0.010 |
Why?
|
Biocompatible Materials | 1 | 1990 | 1683 | 0.010 |
Why?
|
Vitamin B 12 | 1 | 2004 | 524 | 0.010 |
Why?
|
Criminal Psychology | 1 | 2001 | 15 | 0.010 |
Why?
|
Lipid Metabolism | 1 | 2010 | 1893 | 0.010 |
Why?
|
Chi-Square Distribution | 1 | 2007 | 3418 | 0.010 |
Why?
|
Chronic Disease | 2 | 2009 | 9319 | 0.010 |
Why?
|
Orthopedics | 1 | 1990 | 898 | 0.010 |
Why?
|
Hemoglobins | 1 | 2007 | 1525 | 0.010 |
Why?
|
Cough | 1 | 2004 | 594 | 0.010 |
Why?
|
Fasting | 1 | 2007 | 1603 | 0.010 |
Why?
|
Hyperglycemia | 1 | 2009 | 1375 | 0.010 |
Why?
|
Awareness | 1 | 2004 | 649 | 0.010 |
Why?
|
Crime | 1 | 2001 | 204 | 0.010 |
Why?
|
Poisson Distribution | 1 | 2001 | 504 | 0.010 |
Why?
|
Lymphocyte Activation | 1 | 2010 | 5478 | 0.010 |
Why?
|
Employment | 1 | 2004 | 1114 | 0.010 |
Why?
|
Overweight | 1 | 2009 | 2418 | 0.010 |
Why?
|
Primary Prevention | 1 | 2005 | 1185 | 0.010 |
Why?
|
C-Reactive Protein | 1 | 2009 | 3821 | 0.010 |
Why?
|
Behavioral Symptoms | 1 | 1999 | 186 | 0.010 |
Why?
|
Dyspnea | 1 | 2004 | 1347 | 0.010 |
Why?
|
Communicable Diseases | 1 | 2005 | 873 | 0.010 |
Why?
|
Odds Ratio | 1 | 2007 | 9652 | 0.010 |
Why?
|
Health Promotion | 1 | 2007 | 2205 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2020 | 58952 | 0.010 |
Why?
|
Reference Values | 1 | 2002 | 4921 | 0.010 |
Why?
|
Ambulatory Care Facilities | 1 | 2001 | 934 | 0.010 |
Why?
|
Drug Interactions | 1 | 1999 | 1417 | 0.010 |
Why?
|
Patient Compliance | 1 | 2004 | 2688 | 0.010 |
Why?
|
Radiography | 1 | 2004 | 6974 | 0.010 |
Why?
|
Electroencephalography | 1 | 2009 | 6242 | 0.010 |
Why?
|
Sex Factors | 1 | 2007 | 10553 | 0.010 |
Why?
|
Biopsy | 1 | 2004 | 6781 | 0.010 |
Why?
|
Survival Analysis | 1 | 2005 | 10088 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2011 | 15920 | 0.010 |
Why?
|
Insulin | 1 | 2006 | 6588 | 0.010 |
Why?
|
Coronary Disease | 1 | 2005 | 5921 | 0.010 |
Why?
|
Connective Tissue Cells | 1 | 1990 | 49 | 0.010 |
Why?
|
Chromium Alloys | 1 | 1990 | 71 | 0.010 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2004 | 3201 | 0.010 |
Why?
|
Alloys | 1 | 1990 | 110 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2004 | 12976 | 0.010 |
Why?
|
Titanium | 1 | 1990 | 490 | 0.000 |
Why?
|
Algorithms | 1 | 2007 | 14025 | 0.000 |
Why?
|
Diet | 1 | 2004 | 8048 | 0.000 |
Why?
|
Costs and Cost Analysis | 1 | 1989 | 1664 | 0.000 |
Why?
|
Collagen | 1 | 1990 | 2635 | 0.000 |
Why?
|
Cells, Cultured | 1 | 1990 | 18927 | 0.000 |
Why?
|